EHT 899

Drug Profile

EHT 899

Alternative Names: Hepatitis B immunomodulating proteins; Hepatitis B immunomodulation therapy

Latest Information Update: 31 May 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Enzo Biochem
  • Class Antivirals; Viral proteins
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Hepatitis B

Most Recent Events

  • 03 Sep 2009 No development reported - Phase-II for Hepatitis B in Israel (PO)
  • 07 Dec 2006 Clinical development is still ongoing
  • 15 Oct 2001 A phase II study has been added to the Viral Infections therapeutic trials section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top